LeadDiscovery was founded in 1998 by life scientists for life scientists. Based on a solid background of experience from within pharmaceutical R&D our aim is to help companies develop their pipelines through the identification of breaking research and the in depth and expert evaluation of selected therapeutic areas. At the same time we provide a showcase for organizations wishing to increase the exposure of their research to the drug development community. We support the drug discovery and development community through two key service: DailyUpdates & PharmaReports
| Contact Details: |
| Unit 4, Quarry Farm |
| Bodiam |
| East Sussex |
| TN32 5RA |
| United Kingdom |
| Tel: | 44 (0)1580 831877 |
| Fax: | |
| Email: | leaddisc@leaddiscovery.co.uk |
| WWW: | www.leaddiscovery.co.uk/

|
|
Loading...
|
Press Releases on LeadDiscovery:
|
 |
| Emerging oncology treatments: A focus on targeted therapeutics,
|
1st June, 2006 |
Dailyupdates |
Emerging oncology treatments: A
focus on targeted therapeutics, supergeneric reformulations and supportive care
Feb,
2005
Leaddiscovery:
The oncology market is the third largest
|
| COX-2 withdrawal - Therapeutic, R&D and pharmaceutical impact |
1st October, 2004 |
Dailyupdates |
COX-2
withdrawal - Therapeutic, R&D and pharmaceutical impact
October
20 2004.
At
the beginning of October, 2004 Merck withdrew the blockbuster Vioxx (Rofecoxib)
from the market. This move
|
| SOCS1 silencing dramatically increases the anti-cancer efficacy of
|
1st June, 2004 |
Dailyupdates |
SOCS1 silencing dramatically
increases the anti-cancer efficacy of dendritic cell vaccines
5th January, 2005
E.Sussex ,
England: The
development of dendritic cell vaccines to
|
| Gabapentin as a first line treatment of spinal cord injury-related |
1st May, 2004 |
Dailyupdates |
Gabapentin as a first line treatment of spinal cord injury-related
neuropathic pain
DailyUpdates
5th May 2004: As the battle lines are drawn up between gabapentin and its
|
| Results from the PACES trials provides further good news for Pfizer's
|
1st May, 2004 |
Dailyupdates |
Results from the PACES trials provides further good news for Pfizer's Celebrex (celecoxib)
DailyUpdates
10th May 2004: Last week European regulators affirmed the safety of
|
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 188 times since April 2007, the link to the organisation's website has been followed 53 times
Search for more companies in Bodiam
Search for more companies in East Sussex
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
LeadDiscovery